TIDMODX

RNS Number : 1757A

Omega Diagnostics Group PLC

17 January 2020

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Nigerian Ministry of Health approval for VISITECT(R) CD4 350 test

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Company has received approval from the Federal Ministry of Health ("MOH") to enable the VISITECT(R) CD4 350 test to be deployed in Nigeria.

Following a product evaluation in six geopolitical zones in Nigeria, co-ordinated by the National AIDS and Sexually Transmitted Infections Control Programme ("NASCP"), NASCP recommended to the MOH that the Company's VISITECT(R) CD4 350 test be adopted into the National HIV Control Programme as a rapid and instrument-free test device that provides actionable results at the point of care.

MOH approval means the Company's VISITECT(R) CD4 350 test is the first rapid and instrument-free CD4 test to be implemented throughout Nigeria in the care of people living with HIV. As announced on 2 December 2019, we have received initial orders from our distribution partner in Nigeria for 250,000 tests and we will now look to firm up a delivery schedule to determine what proportion of this demand can be shipped prior to the end of the financial year.

Colin King, CEO of Omega commented: "I am pleased that our test has been approved for use in Nigeria which was one of our key strategic aims and allows our unique point-of-care test to make a real difference to people living with HIV in Nigeria."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

 
 Omega Diagnostics Group PLC                                  Tel: 01259 763 030 
 Bill Rhodes, Interim Non-Executive                     www.omegadiagnostics.com 
  Chairman 
  Colin King, Chief Executive 
 Kieron Harbinson, Group Finance 
  Director 
 
 finnCap Ltd                                                  Tel: 020 7220 0500 
 Geoff Nash/Hannah Boros (Corporate 
  Finance) 
 Camille Gochez (ECM) 
 
 Walbrook PR Limited                  Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                 Mob: 07980 541 893 
 Lianne Cawthorne                                             Mob: 07584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCZZGMMGNZGGZM

(END) Dow Jones Newswires

January 17, 2020 05:30 ET (10:30 GMT)

Grafico Azioni Omega Diagnostics (LSE:ODX)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Omega Diagnostics
Grafico Azioni Omega Diagnostics (LSE:ODX)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Omega Diagnostics